The Dentist Entrepreneur Organization and Share Moving Media Announce Joint Venture to Publish DSO-focused Dental Trade Magazine
The Dentist Entrepreneur Organization (DEO) is committed to providing emerging dental group leaders access to the connections, education, and resources they need to grow. So, The DEO is excited to announce its joint venture with Share Moving Media to form DEO Media, LLC, publisher of Efficiency In Group Practice Magazine, a resource for dentist entrepreneurs and DSO leaders.
PORTLAND, Ore. (PRWEB) December 03, 2020
The Dentist Entrepreneur Organization (The DEO) of Portland, Oregon and Share Moving Media of Lawrenceville, Georgia announce the formation of a new entity called DEO Media, LLC, a joint venture between the two organizations to publish Efficiency in Group Practice, a bi-monthly dental trade magazine focused on DSOs (dental service organizations) and group dentistry.
“We’re extremely excited to give emerging dental group leaders even more access to the people, education, and resources they need to grow,” said Jacob Puhl, CEO of The DEO. “This partnership further enables us to continue our mission to help dentist entrepreneurs and their executives fulfill their visions. We hope to have a continued positive impact on the dental community.”
Efficiency In Group Practice provides an informational and educational link between manufacturers, distributors, service providers, and dental group practices. Each issue of Efficiency covers emerging trends in dentistry, and provides content to enable group practices to capitalize on their distinct strengths and differences to reach new heights of efficiency and become more profitable.
“This new partnership positions Efficiency in Group Practice with the leadership and direction so dearly needed for a publication to thrive in these dynamic times,” said Share Moving Media CEO John Pritchard. “Now more than ever, dental group practices need insight, understanding and community to grow their practices. We are excited to partner with Jacob Puhl and the entire DEO team to help provide just that!”
Under the partnership, The DEO and Share Moving Media will collaborate on editorial, sales, marketing and distribution of the industry-leading publication. Jacob Puhl, partner and CEO of the Dentist Entrepreneur Organization, will be Efficiency’s publisher.
The first issue from DEO Media, LLC will be the January-February 2021 edition of Efficiency In Group Practice.
The Dentist Entrepreneur Organization© (DEO) provides a context, a professional resource, and a peer-to-peer network within a well-managed organizational structure. For more information, visit https://deodentalgroup.com/.
Share Moving Media is a leading publishing and content company providing information, communication and educational services to providers, manufacturers and distributors involved in the business of healthcare. For more information, visit https://sharemovingmedia.com/.
For more information on Efficiency in Group Practice, visit https://www.dentalgrouppractice.com/.
For the original version on PRWeb visit: https://www.prweb.com/releases/the_dentist_entrepreneur_organization_and_share_moving_media_announce_joint_venture_to_publish_dso_focused_dental_trade_magazine/prweb17583024.htm
TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies
Companies to collaborate in first-of-its-kind uses of Thin Film Freezing technology applied to monoclonal antibodies
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling breakthroughs in medicine through immune profiling, today jointly announce that both companies have entered into a worldwide Joint Development and Collaboration Agreement to develop novel commercial products incorporating Augmenta’s human-derived monoclonal antibodies (mAbs) for potential COVID-19 therapeutics.
Under the terms of the Agreement, both companies will collaborate in a Joint Development Project to develop one or more commercial therapeutics based on, derived from, and/or incorporating Augmenta’s human monoclonal antibodies to potentially treat patients with COVID-19. These products will be developed utilizing TFF Pharmaceuticals’ Thin-Film Freezing technology to manufacture dry powder formulations of these specific mAbs for inhalation delivery directly to the lungs of patients. The Agreement also includes the development of formulations suitable for parenteral administration, where the Thin Film Freezing dry powder formulations can be reconstituted, potentially mitigating the impacts of cold-chain storage and handling. TFF Pharmaceuticals will also have the option to develop two additional Augmenta mAbs for indications other than COVID-19.
Augmenta Bioworks and TFF Pharmaceuticals will allocate patent license rights to their respective technologies to allow each company to jointly commercialize the products developed under the Joint Development Project. The companies have agreed to a 50-50 split of all costs and expenses to further the Joint Development Project and both companies have agreed to the same 50-50 split of all revenues, cash payments and/or future cash payments related to the sale and/or license of the products resulting from the Joint Development Project to a third party.
“This important agreement represents the culmination of many months of work by our scientific team, as we work towards the development of a never-before-achieved formulation of monoclonal antibodies into a dry powder therapeutic,” said Glenn Mattes, CEO, of TFF Pharmaceuticals, Inc. “It is a testament to the remarkable flexibility and capability of our Thin Film Freezing platform and we are eager to develop these potentially breakthrough mAb therapies internally, along with our other programs in Invasive Pulmonary Aspergillosis, solid organ transplant anti-rejection, and botanicals.”
“Confirmed discovery of novel anti-SARS-Cov-2 antibodies in 8 days was an achievement made possible by years of technology development, and a clear indication of the power and potential of our platform,” said Christopher Emig, Ph.D., CEO and Co-Founder of Augmenta Bioworks, Inc. “We are excited to enter this partnership to bring our COVID-19 treatment into clinical development, and are looking forward to the world’s first effective, affordable and scalable antibody therapeutic to mitigate the devastating effects of this disease.”
“We believe the interest in monoclonal-antibody therapeutics for the treatment of COVID-19 is extremely high, with the promise that they will harness the immune system’s natural response to viral invaders,” said Robert O. Williams III, Ph.D., Division Head of the University of Texas at Austin’s Division of Molecular Pharmaceutics and Drug Delivery and inventor of TFF Pharmaceuticals’ Thin Film Freezing technology.
The first lady told Florida rallygoers at her first campaign event with her husband in 2020 that “health care for every citizen remains a priority for him, and as you have seen over these past years, he won’t stop until he gets it done.”
But in reality, Trump has made repealing the Affordable Care Act a cornerstone of his candidacy and presidency, pledging back in 2016 that he would undo the law that not only gave millions of Americans access to health insurance, but also provided protections for those with pre-existing conditions and entitled people to receive free preventive health care services.
In her swing state pitch less than a week before Election Day, the first lady focused largely on the President’s accomplishments from his first term and echoing some of her husband’s campaign themes.
“For those of you still deciding who to vote for on Tuesday, I hope what I have to say will prove to you that a vote for President Trump is a vote for a better America,” the first lady said.
She also criticized those who are playing politics with a coronavirus vaccine, but her remarks were delivered to a crowd of supporters where social distancing was not observed and masks were largely not worn.
“A vaccine is not a partisan issue. If you are not supporting the safe production of a vaccine, you’re not supporting the health and safety of the American people,” she said. “There is no room to play politics on this topic in the midst of [a] pandemic.”
By Steven Reinberg, HealthDay Reporter
FRIDAY, Oct. 23, 2020 (HealthDay News) — High levels of a protein that lubricates the knee joint may actually be a harbinger of impending joint disease, a surprising animal study suggests.
The researchers looked at the role of the protein, known as lubricin, in anterior cruciate ligament (ACL) injuries in dogs because it may also be involved in similar injuries in humans.
“Lubricin is crucial for normal joint function and the lubrication of cartilage,” said researcher Heidi Reesink, an assistant professor in equine health at the College of Veterinary Medicine at Cornell University. “We know that if a person or animal doesn’t make that protein, they will develop devastating joint disease affecting all the major weight-bearing joints.”
But Reesink found that in dogs that suffered a ligament tear in the knee, lubricin levels increased within the joint, which is the opposite of the conventional assumptions. “The dogma in this field has been that lubricin decreases in joint disease,” Reesink said in a university news release.
The researchers found that in three dogs, lubricin increased in the time between the initial injury but before any signs of arthritis.
“This indicates that the presence of increased lubricin might actually be a biomarker for predicting future osteoarthritis,” Reesink said. “We also saw increased lubricin in dogs months to years after they injured their ACLs, suggesting that lubricin might be an indicator of ongoing joint instability.
“In looking at horses and dogs, we’re seeing the same pattern,” Reesink said. “The strongest piece of data would be to show it in humans as well.” However, findings in animal studies don’t always translate to humans.
Increased lubricin could become a signal for doctors to intervene or try a different treatment, she added.
The study was published recently in the journal Scientific Reports.
Copyright © 2020 HealthDay. All rights reserved.
LOS ANGELES, Oct. 20, 2020 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported it has executed a partnership agreement with Adventist Health to create an outpatient imaging joint venture in Simi Valley, California to initially include three outpatient facilities.
Under the new joint venture, RadNet will contribute two of its Simi Valley imaging Centers, Alamo Advanced Imaging and Simi Valley Advanced Imaging, and Adventist Health will contribute its Aspen Imaging Center. The facilities will together operate MRI, CT, PET/CT, Ultrasound and X-ray modalities.
In addition, RadNet will assume the operational management of Adventist Health’s Nancy Reagan Breast Center, which will perform mammography, breast ultrasound, imaging-guided biopsies and related women’s health services.
Simi Valley, California has a population of approximately 125,000 and is located in the southeast corner of Ventura County, approximately 40 miles from downtown Los Angeles. The joint venture is expected to begin operations no later than January of 2021.
Dr. Howard Berger, Chairman and Chief Executive Officer of RadNet, noted, “We are pleased to announce our new affiliation with Adventist Health, one of the largest health systems on the west coast of the continental United States and Hawaii. Together, both companies have identified an exciting opportunity in the Simi Valley marketplace, a medical community were Adventist Health’s commitment includes the ownership of the leading hospital, an urgent care center, a clinical laboratory, homecare services and various family and specialty physician practices. Aligning with such a high-quality and devoted partner will enhance the service offerings to the referring physician and patient communities of Simi Valley.”
“Adventist Health is pleased to partner with RadNet, the nation’s leading outpatient radiology provider. Our joint venture will advance our imaging capabilities in the region and will provide our medical community with an integrated radiology network offering the full scope of imaging services,” added Jennifer Swenson, President, Adventist Health Simi Valley.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 332 owned and/or operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, New Jersey, New York, and now Arizona. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of over 8,600 employees. For more information, visit http://www.radnet.com.
About Adventist Health
Adventist Health is a faith-based, nonprofit integrated health system serving more than 80 communities on the West Coast and Hawaii. Founded on Seventh-day Adventist heritage and values, Adventist Health provides care in hospitals, clinics, home care agencies, hospice agencies, and joint-venture retirement centers in both rural and urban communities. Our compassionate and talented team of 37,000 includes associates, medical staff physicians, allied health professionals, and volunteers driven
Osteoarthritis is the most common type, and it happens when the cartilage in the joint breaks down and the surrounding bone develops inflammation. Osteoarthritis becomes more common with age, but you don’t have to just grit your teeth and suffer through it, says Jason McDougall, a professor at Dalhousie University in Canada who specializes in arthritis and pain research.
An array of strategies are available for treating joint pain, ranging from physical therapy to pain medications, injections and surgery, but one of the most effective ways to manage joint discomfort is one that can seem counterintuitive: Keep moving.
If you’re feeling pain in your joints, you might be inclined to lay off them, but that’s one of the worst things you can do, says A. Lynn Millar, a physical therapist and fellow emeritus at the American College of Sports Medicine.
It’s a vicious cycle — it hurts, so you stop moving the area that’s painful, but “immobilization actually causes deterioration in the joints,” Millar says. Hence the saying among physical therapists, “Motion is lotion.” Movement brings nutrients to the joints and keeps them healthy, Millar says. “Everyone wants a magic bullet,” she says, and physical activity is the closest thing we have.
Even if you’ve had an X-ray or MRI that shows arthritic changes in your joint, that shouldn’t dissuade you from exercising. “Your structure isn’t your destiny,” says Greg Lehman, a Toronto-based physiotherapist, chiropractor and clinical educator in physiotherapy.
Turns out, the findings on an imaging test aren’t a good indicator of pain, he says. Imagine going to a ski area and finding all the people 50 and older who were skiing around enjoying themselves. Lehman says that if you gave these skiers a scan of their knees and hips, the “vast majority of them” would have structural changes in their knee and hips without even knowing about it.
For a 2012 study, researchers took MRIs of the knees of 710 people 50 and older and found that nearly 90 percent had at least one feature of osteoarthritis on the MRI, irrespective of whether they had knee pain.
An X-ray or MRI is not a good indicator of whether someone has pain, Lehman says. “It’s not that those changes you can see in a joint or tendon or muscle are irrelevant,” he says, but they are not very good at predicting how someone feels or what they can do.
Joint pain is complicated, and it’s not just about what’s going on with your bones and ligaments, but also how your nervous system is interpreting the signals it’s receiving.
Chemical mediators, such as enzymes and neuropeptides, released into the joint when someone has arthritis can sensitize the nerve endings around it to make them more active than normal. “These signals are translated by the brain as pain,” McDougall says.
Researchers are just starting to characterize the different kinds of chemical mediators that might be involved in these pain signals, he says.
Most people with joint pain respond well to physical